Hotline: 1-866-737-5999

SDS/MSA FAQ - PDF Download 
Home |About Us |Support |Education |Research |Advocacy |Fundraising| Contact Us
History of SDS/MSA Charity
Position Statement
MSA Forums
The MSA Blog
MSA Events
Annual Conference
Sophies Search for a Cure DVD
Movement Disorder Clinics
Doctors & Clinics
Common Symptoms of MSA
Diagnosing MSA
MSA Demographics
MSA Description by NIH
MSA vs Parkinsons
Sympathetic Nerves in MSA
Neurogenic Orthostatic Hypotension
MSA Glossary of Terms
Annual Conference DVD
The MSA Research Fund
MSA Research Grants
Research Grant Application Form
AAS - MSA Research Award
MSA Research Updates/Results
What is the ANS
Board of Directors
MSA Coalition Press Releases
Position Statement
MSA Coalition History
Waters Pressor Effect
Shop Now - MSA Tee Shirts
The MSA Research Fund
Start a Fundraiser
Memorial Envelopes
MSA Advocacy
The MSA Blog
Support Group Meeting DVD
Sophies Search for a Cure
Annual MSA Conference
Doctors and Clinics
SDS/MSA Clinical Trials
Local Support Groups
Hospice Information
Board of Directors
Site Map

Study to evaluate the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.

View the study on the website

TEVA Pharmaceuticals Industries, LTD
. is currently recruiting patients for a phase IIb clinical study designed to evaluate the efficacy, safety, and tolerability of Rasagiline Mesylate 1 mg in patients with multiple system atrophy of the parkinsonian subtype (MSA-P).

Multiple system atrophy (MSA) is a neurodegenerative disease marked by a combination of symptoms affecting movement, blood pressure, and other body functions; hence the label "multiple system" atrophy. The cause of MSA is unknown.
The purpose of this study is to test the clinical effect of rasagiline on people with Multiple System Atrophy of the parkinsonian subtype (initials symptoms are similar to Parkinson’s disease).

Eligible Study participants will receive either rasagiline mesylate or matching placebo for 48 weeks and will be evaluated every 6 weeks by phone/or in-clinic visits.

People with signs of advanced MSA, people who are taking certain excluded medications, and people with other existing conditions will be excluded from the study. A detailed evaluation for eligibility will be conducted by the study physician.
More information including participating study sites may be found on the study’s webpage:

View the study on the website